FDA Grants Priority Review for Genentech ’s Ocrevus (ocrelizumab) Biologics License Application

South San Francisco, CA -- June 27, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company ’s Biologics License Application (BLA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news